ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO1171

Endothelin-1 Promotes Renal Iron Deposition in Murine Models of Iron Overload

Session Information

Category: Anemia and Iron Metabolism

  • 201 Anemia and Iron Metabolism: Basic

Author

    Group or Team Name

    • Rachel Meek. The University of Alabama at Birmingham, Birmingham, AL.
    Background

    Recent observations show that renal iron deposition correlates with plasma endothelin-1 (ET-1) in sickle cell disease (SCD). Iron accumulation in humanized SCD mice kidneys is ameliorated by a selective endothelin A receptor (ETA) antagonist, ambrisentan. Thus, we hypothesized that endothelial-derived ET-1 regulates iron trafficking in the kidney.

    Methods

    Vascular endothelial cell ET-1 knockout (VEET KO) male mice aged 12 weeks were injected with phenylhydrazine (40 mg/kg, IP) for two consecutive days to induce hemolysis and consequent iron overload. Heme oxygenase-1 knockout (HO-1 KO) mice, a model of iron overloading, aged 20 weeks were given ambrisentan (10 mg/kg/day, p.o.) for 4 weeks.

    Results

    VEET KO mice exhibited a higher survival rate relative to littermate control mice (66.7% vs 20% survival, n=9 and 5, respectively). Moreover, VEET KO mice with induced hemolysis have less renal iron deposition when compared with control mice (Prussian blue staining, 41.1 ± 5.1 vs 79.3 ± 0 Mpixel/μm, respectively). At baseline, iron trafficking mediators (TRF-1, DMT-1, FtH, FPN-1) assessed by RT-PCR were not upregulated in VEET KO mice when compared with control mice.

    HO-1 KO mice exhibited elevated plasma ET-1 (2.59 ± 0.78 vs 0.45 ± 0.09 pg/mL), cortical ET-1 mRNA expression (2-fold increase), and renal iron content (87.2 ± 27.5 vs 0.24 ± 0.2 Mpixel/μm) when compared with control mice; all were significantly reduced by ambrisentan. No significant changes in expression of iron uptake and storage mediators in KO mice. Ferroportin-1, an iron exporter, was significantly increased by ambrisentan.

    Conclusion

    These data suggest ET-1 contributes to renal iron overload.